CSIMarket Company Name, Ticker, Suppliers, else..
 
Biostax Corp  (BTAX)
 

Biostax's Customers Performance

BTAX


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
BTAX's Source of Revenues

• List of BTAX Customers




for the same period Biostax Corp

• List of BTAX Customers





Biostax's Comment on Sales, Marketing and Customers



The company markets and distributes Lodonal™, an immune system regulator approved by NAFDAC for HIV/AIDS treatment in Nigeria. Lodonal™ is the only product with regulatory approval for low dose naltrexone therapy for HIV in that market. The company focuses on markets with high unmet medical needs and lower barriers to entry, including regions outside the U.S. such as Africa. It is developing the investigational drug JKB-122 for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Clinical trials of Lodonal have demonstrated immune modulatory and anti-inflammatory effects beneficial to people living with HIV. The company plans to generate revenue from Lodonal sales in Africa through manufacturing, sales, and distribution partnerships managed by its wholly owned subsidiary, TNIB International (TNI). It also intends to pursue expanded approval for Lodonal under a modified agreement with AHAR Pharm and Biostax.





Biostax’s Comment on Sales, Marketing and Customers


The company markets and distributes Lodonal™, an immune system regulator approved by NAFDAC for HIV/AIDS treatment in Nigeria. Lodonal™ is the only product with regulatory approval for low dose naltrexone therapy for HIV in that market. The company focuses on markets with high unmet medical needs and lower barriers to entry, including regions outside the U.S. such as Africa. It is developing the investigational drug JKB-122 for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Clinical trials of Lodonal have demonstrated immune modulatory and anti-inflammatory effects beneficial to people living with HIV. The company plans to generate revenue from Lodonal sales in Africa through manufacturing, sales, and distribution partnerships managed by its wholly owned subsidiary, TNIB International (TNI). It also intends to pursue expanded approval for Lodonal under a modified agreement with AHAR Pharm and Biostax.







BTAX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Biostax Corp 0.02 0.00 -1.87 -
SUBTOTAL 0.00 0.00 0.00 -

Sources: Biostax Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Biostax Corp’s corporate clients.
For your research, we’ve provided 9 tables on Biostax Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.